Skip to main content

Table 2 Descriptive statistics of change in mGFR, eGFR (Cockcroft-Gault) and serum creatinine (full analysis set)

From: Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

  mGFR (mL/min/1.73 m 2 ) eGFR (Cockcroft-Gault) (mL/min/1.73 m 2 ) Serum creatinine (mg/dL)
  Tofacitinib → placebo group Placebo → placebo group Tofacitinib → placebo group Placebo → placebo group Tofacitinib → placebo group Placebo → placebo group
Baseline
 Number 97 51 97 51 97 51
 Mean (SD) 88.98 (18.79) 89.67 (21.33) 104.19 (28.42) 111.30 (26.91) 0.77 (0.15) 0.76 (0.17)
 Median (Q1, Q3) 87.98 (75.76, 99.98) 86.99 (75.17, 98.20) 97.22 (82.43, 125.57) 107.22 (91.47, 134.89) 0.76 (0.67, 0.85) 0.75 (0.64, 0.84)
Change at end of period 1 from baseline
 Number 91 46 92 46 92 46
 Mean (SD) −6.73 (16.44) −0.50 (17.34) −3.59 (10.31) 1.28 (11.48) 0.03 (0.07) −0.00 (0.07)
 Median (Q1, Q3) −6.46 (−11.85, 2.14) 0.82 (−5.48, 6.79) −3.36 (−9.18, 2.86) 2.30 (−5.71, 6.14) 0.02 (−0.02, 0.08) −0.01 (−0.05, 0.04)
Change at end of period 2 from baseline
 Number 86 45 87 44 87 44
 Mean (SD) −3.02 (17.55) −5.96 (20.66) 0.03 (10.15) 0.48 (9.54) 0.00 (0.07) −0.00 (0.05)
 Median (Q1, Q3) −3.41 (−8.55, 3.65) −3.88 (−9.13, 7.58) −0.32 (−6.05, 5.74) 0.18 (−3.81, 4.28) 0.00 (−0.05, 0.05) 0.00 (−0.03, 0.03)
Change at end of period 2 from end of period 1
 Number 86 45 87 44 87 44
 Mean (SD) 2.92 (19.02) −5.41 (16.65) 3.71 (11.95) −0.97 (10.06) −0.03 (0.08) 0.00 (0.07)
 Median (Q1, Q3) 1.68 (−3.60, 8.62) −3.25 (−12.24, 2.29) 2.94 (−4.45, 10.31) −2.07 (−7.29, 6.09) −0.02 (−0.07, 0.03) 0.01 (−0.04, 0.05)
  1. eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate; Q1, 25th percentile; Q3, 75th percentile; SD, standard deviation.
\